Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation
Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distri...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9c07b5e0e76a48a6bd7159b323bcca98 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9c07b5e0e76a48a6bd7159b323bcca98 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9c07b5e0e76a48a6bd7159b323bcca982021-12-01T02:53:08ZLeft Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation2296-418510.3389/fbioe.2021.725121https://doaj.org/article/9c07b5e0e76a48a6bd7159b323bcca982021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fbioe.2021.725121/fullhttps://doaj.org/toc/2296-4185Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls.Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm.Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022).Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection.Hansuk KimHansuk KimHansuk KimHana SheittHana SheittHana SheittHana SheittHana SheittStephen B. WiltonStephen B. WiltonJames A. WhiteJames A. WhiteJulio GarciaJulio GarciaJulio GarciaJulio GarciaJulio GarciaFrontiers Media S.A.article4D-flow MRIflow distributionmagnetic resoance imagingdirect flowarial fibrillationBiotechnologyTP248.13-248.65ENFrontiers in Bioengineering and Biotechnology, Vol 9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
4D-flow MRI flow distribution magnetic resoance imaging direct flow arial fibrillation Biotechnology TP248.13-248.65 |
| spellingShingle |
4D-flow MRI flow distribution magnetic resoance imaging direct flow arial fibrillation Biotechnology TP248.13-248.65 Hansuk Kim Hansuk Kim Hansuk Kim Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Stephen B. Wilton Stephen B. Wilton James A. White James A. White Julio Garcia Julio Garcia Julio Garcia Julio Garcia Julio Garcia Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| description |
Introduction: Four-dimensional (4-D) flow cardiac magnetic resonance imaging can be used to elegantly describe the hemodynamic efficiency of left ventricular (LV) flow throughout the cardiac cycle. Patients with nonvalvular paroxysmal atrial fibrillation (PAF) may have occult LV disease. Flow distribution analysis, based on 4-D flow, may unmask the presence of LV disease by assessing flow components: direct flow, retained flow, delayed ejection, and residual volume. This study aimed to identify LV hemodynamic inefficiencies in patients with PAF and normal systolic function. We hypothesized that the fraction of direct flow to the total end-diastolic volume would be reduced in patients with PAF compared with controls.Methods: We used 4-D LV flow component analysis to compare hemodynamics in 30 healthy controls and 50 PAF patients in sinus rhythm.Results: PAF subjects and healthy controls had similar LV mass, volume, and ejection fraction. Direct flow was lower in the PAF group than in the controls (44.5 ± 11.2% vs. 50.0 ± 12.2%, p = 0.042) while delayed ejection was higher in the PAF group (21.6 ± 5.6% vs. 18.6 ± 5.7%, p = 0.022).Conclusion: PAF patients demonstrated a relative reduction in direct flow and elevation in delayed ejection. |
| format |
article |
| author |
Hansuk Kim Hansuk Kim Hansuk Kim Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Stephen B. Wilton Stephen B. Wilton James A. White James A. White Julio Garcia Julio Garcia Julio Garcia Julio Garcia Julio Garcia |
| author_facet |
Hansuk Kim Hansuk Kim Hansuk Kim Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Hana Sheitt Stephen B. Wilton Stephen B. Wilton James A. White James A. White Julio Garcia Julio Garcia Julio Garcia Julio Garcia Julio Garcia |
| author_sort |
Hansuk Kim |
| title |
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| title_short |
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| title_full |
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| title_fullStr |
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| title_full_unstemmed |
Left Ventricular Flow Distribution as a Novel Flow Biomarker in Atrial Fibrillation |
| title_sort |
left ventricular flow distribution as a novel flow biomarker in atrial fibrillation |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/9c07b5e0e76a48a6bd7159b323bcca98 |
| work_keys_str_mv |
AT hansukkim leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hansukkim leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hansukkim leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hanasheitt leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hanasheitt leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hanasheitt leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hanasheitt leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT hanasheitt leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT stephenbwilton leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT stephenbwilton leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT jamesawhite leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT jamesawhite leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT juliogarcia leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT juliogarcia leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT juliogarcia leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT juliogarcia leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation AT juliogarcia leftventricularflowdistributionasanovelflowbiomarkerinatrialfibrillation |
| _version_ |
1718405918795759616 |